Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Global trends in clinical trials of ivermectin for COVID-19—Part 2

Yagisawa et al., The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.77.1_45
Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Review of global trends in clinical trials of ivermectin for COVID-19. The review summarizes and analyzes the results of trials to date. Authors report that 27 systematic reviews and meta-analyses have been conducted, with 15 demonstrating ivermectin efficacy. Authors conclude that COVID-19 has changed over time, limiting standard meta-analysis without addressing the changes, unlike other chronic diseases. Several important trials were found to have serious errors or protocol violations.
Reviews covering ivermectin for COVID-19 include1-38.
Yagisawa et al., 25 Mar 2024, peer-reviewed, 4 authors.
This PaperIvermectinAll
{ 'DOI': '10.11553/antibiotics.77.1_45', 'URL': 'https://doi.org/10.11553/antibiotics.77.1_45', 'language': 'en', 'title': 'Global trends in clinical trials of ivermectin for COVID-19—Part 2', 'author': [ {'given': 'Morimasa', 'family': 'Yagisawa, Ph.D.'}, {'given': 'Patrick', 'family': 'J. Foster, M.D.'}, {'given': 'Hideaki', 'family': 'Hanaki, Ph.D.'}, {'given': 'Satoshi', 'family': 'Ōmura, Ph.D.'}], 'publisher': 'Japan Antibiotics Research Association', 'issued': {'date-parts': [[2024, 3, 25]]}, 'volume': '77', 'number': '1', 'page': '45-92', 'ISSN': ['03682781', '03682781', '21865477'], 'container-title': 'The Japanese Journal of Antibiotics'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit